Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer

S. Al-Samsam, J. Bartos, V. Samal, J. Dvorak, H. Kolarova, I. Richter

. 2024 ; 29 (1) : 1-9. [pub] 20240318

Status not-indexed Language English Country Poland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24018371

BACKGROUND: The aim was to assess therapeutic outcomes and tolerance in patients with metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor targeted agents (ARTA) treatment at one oncological center in the Czech Republic. MATERIALS AND METHODS: Retrospective analysis of 64 patients with mCRPC treated with abiraterone (50 patients) and enzalutamide (14 patients) in the first line of this disease was conducted. Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. RESULTS: The median follow-up was 28.4 months. The median PFS was 15.4 months [95% confidence interval (CI): 12.3-18.5], median OS was 38.2 months (95% CI: 19.9-56.5). Regression analysis demonstrated a favorable prognostic effect on PFS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of prostate-specific antigen (PSA) ≥ 50% within 3 months, in patients younger than 74 years and in overall performance status (PS) 0. Regression analysis demonstrated a favorable prognostic effect on OS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of PSA ≥ 50 % within 3 months and in patients with overall PS 0. Adverse effects grade 3-4 were reported in 17 (27.9%) patients in abirateron arm and in 1 (7.1%) patient in enzalutamide arm. CONCLUSION: The analysis of patients with mCRPC treated with ARTA in the first line showed that ARTA represents an effective and safe therapy and contributes to longer survival.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018371
003      
CZ-PrNML
005      
20241016081851.0
007      
ta
008      
241008s2024 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5603/rpor.99028 $2 doi
035    __
$a (PubMed)39165601
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Al-Samsam, Sofya $u Department of Oncology, Regional Hospital Liberec, Czech Republic
245    10
$a Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer / $c S. Al-Samsam, J. Bartos, V. Samal, J. Dvorak, H. Kolarova, I. Richter
520    9_
$a BACKGROUND: The aim was to assess therapeutic outcomes and tolerance in patients with metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor targeted agents (ARTA) treatment at one oncological center in the Czech Republic. MATERIALS AND METHODS: Retrospective analysis of 64 patients with mCRPC treated with abiraterone (50 patients) and enzalutamide (14 patients) in the first line of this disease was conducted. Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. RESULTS: The median follow-up was 28.4 months. The median PFS was 15.4 months [95% confidence interval (CI): 12.3-18.5], median OS was 38.2 months (95% CI: 19.9-56.5). Regression analysis demonstrated a favorable prognostic effect on PFS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of prostate-specific antigen (PSA) ≥ 50% within 3 months, in patients younger than 74 years and in overall performance status (PS) 0. Regression analysis demonstrated a favorable prognostic effect on OS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of PSA ≥ 50 % within 3 months and in patients with overall PS 0. Adverse effects grade 3-4 were reported in 17 (27.9%) patients in abirateron arm and in 1 (7.1%) patient in enzalutamide arm. CONCLUSION: The analysis of patients with mCRPC treated with ARTA in the first line showed that ARTA represents an effective and safe therapy and contributes to longer survival.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bartos, Jiri $u Department of Oncology, Regional Hospital Liberec, Czech Republic
700    1_
$a Samal, Vladimir $u Department of Urology, Regional Hospital Liberec, Czech Republic
700    1_
$a Dvorak, Josef $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Kolarova, Hana $u MATSTAT, Prague, Czech Republic
700    1_
$a Richter, Igor $u Department of Oncology, Regional Hospital Liberec, Czech Republic $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic $u Technical University of Liberec, Czech Republic
773    0_
$w MED00154188 $t Reports of Practical Oncology and Radiotherapy $x 1507-1367 $g Roč. 29, č. 1 (2024), s. 1-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39165601 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081847 $b ABA008
999    __
$a ok $b bmc $g 2196543 $s 1230324
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 29 $c 1 $d 1-9 $e 20240318 $i 1507-1367 $m Reports of Practical Oncology and Radiotherapy $n Rep Pract Oncol Radiother $x MED00154188
LZP    __
$a Pubmed-20241008

Find record

Citation metrics

Archiving options